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Abstract
Background: Tuberculosis (TB) is one of the most prevalent cause of death due to a single pathogen. Bacillus Calmette 
Guérin (BCG) is the only vaccine available for clinical use that protects against miliary TB; however, this vaccine has 
shown variable levels of efficacy against pulmonary TB. In India, a single dose of BCG vaccine is given and there are few 
countries where repeated doses of BCG are given. The incidence of TB in India is very high inspite of primary 
vaccination in neonatal period and therefore requires consideration for repeated immunization.
Methods: To improve BCG immunogenicity, we have evaluated specific antimycobacterial immune responses (anti-
BCG IgG and IFN-γ), T cell activity-ADA, CD4 and CD8 T cell count, and CD4/CD8 ratio in a peripheral blood 
mononuclear cells (PBMC) model using boost immunization protocols with the BCG vaccine. PBMC were induced with 
a repeat dose of BCG at 24 and 72 hrs of cell culture.
Results: At the end of the experimental time, supernatant was collected to estimate anti-BCG IgG titer, interferon γ, 
ADA activity, CD 4 and CD8 T cell count, and CD4/CD8 ratio. We demonstrated that PBMC induced with a repeat dose 
of BCG showed an increased specific anti-mycobacterial immune responses, T cell activity, and ADA activity as 
compared to PBMC induced with BCG alone or without BCG induction.
Conclusion: The repeat BCG stimulation of PBMC obtained from BCG vaccinated individuals shows enhanced immune 
activation with respect to increased anti-BCG titre, IFN-γ and ADA activity without concomitant increase in CD4 and 
CD8 cells. This study provides some basic data in future experiments in animal models with respect to repeat BCG 
vaccination.
Introduction
In India, tuberculosis (TB) is the greatest cause of death
due to a single pathogen. Bacillus Calmette-Guerin
(BCG) is the only vaccine available for clinical use and is
one of the most widely used vaccines, being both inex-
pensive and safe [1,2]. Despite early success, the BCG
vaccine has had a limited effect against the incidence of
TB in the developing world. Various clinical trials have
demonstrated that BCG showed variable levels of efficacy
against pulmonary TB. For example, a major trial in the
United Kingdom showed >75% protection [3]; however,
trials in south India and Malawi demonstrated that BCG
failed to protect consistently against pulmonary TB [4,5].
The reasons for this have been a matter of debate and this
indicates an urgent need for more effective vaccines to
decrease the incidence of tuberculosis.
Current research interest has been directed towards
improving the immunogenicity of BCG [6]. Recently,
recombinant BCG expressing ESAT-6 was found to con-
fer enhanced protection against tuberculosis compared to
normal BCG [7]. Similarly, it has been demonstrated that
the recombinant BCG vaccine expressing the Mycobacte-
rium tuberculosis 30-kDa major secretory protein
induced greater protective immunity against tuberculosis
than the conventional BCG vaccine [8]. A different
approach is the heterologous expression of cytokines in
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BCG [9,10] or of bacterial proteins, such as Listeria
monocytogenes listeriolysin, which improves the capacity
to stimulate antimycobacterial T-cell responses [11,12].
An interesting complementary approach to improving
BCG immunogenicity is its combination in prime-boost
immunization protocols [3,5]: priming with a DNA vac-
cine that expresses antigen 85B and boosting with BCG
improves the protective efficacy in a murine M. tubercu-
losis challenge model [8]. In spite of all these efforts, no
new TB vaccine has been developed in the last 85 years as
an alternative to BCG. This suggests that instead of devel-
oping several new molecules, a focus can be placed on the
improvement of the current BCG vaccination protocol,
which is the objective of our studies.
There are some countries that give repeated doses of
BCG vaccine. For example, Turkey gives BCG immuniza-
tion four times: during infancy at two months after birth,
at six to seven years of age (first grade), at eleven to twelve
years of age (fifth grade), and sixteen to seventeen years
of age (high school) [13]. In India, a single dose of BCG
vaccine is given within one week of the birth of child. The
incidence of TB in India is very high and repeated immu-
nization is needed as it is done in other countries. How-
ever, it is very difficult to start giving repeated doses of
BCG in India without any experimental studies. The aim
of the present study is to investigate the immune
responses to repeated stimulation of PBMC's from BCG
vaccinated healthy volunteers with BCG vaccine.
Materials and methods
Study Subjects
Participants were recruited for this study under protocols
approved by the ethics committee of Central India Insti-
tute of Medical sciences (CIIMS), Nagpur, India and
enrolled after obtaining informed consents. All the sub-
jects aged 18-45 years were recruited having no history of
pulmonary illness, tuberculosis, seronegative for HIV and
HBV and had been vaccinated with BCG.
PBMC model
PBMCs were separated from whole blood of healthy vol-
unteers (n = 15) included in this study by density gradient
centrifugation using the Ficoll Histopaque method. BCG
vaccine (Moscow Strain) was obtained from Serum Insti-
tute of India, Pune and stored at 4-8°C. Prior to use, vac-
cine was reconstituted in sterile saline. After counting,
the cells were cultured in RPMI-1640 medium keeping
the concentration at 2 × 105 cells/well and were induced
with the BCG vaccine (10 μl/ml or 104 CFU/ml). The cells
not induced with BCG vaccine were taken as controls.
Induced cells were then incubated for 0, 4, 24, 48, 72, 96,
and 120 hrs in a CO2 incubator. Booster doses of BCG (10
μl) were given after 24 and 72 hrs. The cells were then
taken out from the incubator and were centrifuged for 10
mins at 1000 rpm. Supernatant was separated and was
analyzed for anti-BCG IgG titer, adenosine deaminase
activity, and interferon γ levels. The pellet was suspended
in phosphate buffer saline (pH 7.2) and was used for flow
cytometry analysis to determine CD 4 and CD 8 T cell
count. The detailed experimental sketch is given in
figure 1.
Anti-BCG (IgG) estimation
An in-house developed Indirect ELISA method was
employed using a BCG vaccine. (Bacillus Calmette
Guerin strain, Serum Institute Of India Ltd, Pune, India)
to estimate the Anti-BCG (IgG) titer/level. Briefly the 96-
well microtiter plate (MaxisorpImmunoplate, Nalge
Nunc International, Naperville, III.) were coated with 10
ng of BCG (diluted in sterile saline). After 3 hours of
incubation at 37°C, the plates were washed and blocked
with 0.25% BSA in Phosphate buffered saline (PBS) pH
7.40. After 60 minutes of incubation, plates were washed
once and kept overnight at 4°C. Next day the plates were
incubated with supernatant (1:400 diluted) in PBS. After
45 minutes of incubation plates were washed and incu-
bated with rabbit anti-mouse IgG, HRP conjugate
(1:10,000) for 45 minutes. For color development sub-
strate Tetramethyl benzidine in hydrogen peroxide
(TMB/H2O2) was added and incubated for 10 min. The
reaction was stopped by adding 2.5N sulphuric acid and
the optical density of plates was read at 450 nm.
Interferon γ (gamma)
IFN-γ was measured by an enzyme linked immunosor-
bant assay (ELISA) according to the manufacturer's
instructions (Bender Med System, Austria). In brief, anti
IFN-γ monoclonal coating antibody was adsorbed onto
the microwells. After two hours of incubation at room
temperature, the wells were washed and blocked with
0.5% BSA in phosphate buffer. After one hour of incuba-
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tion at room temperature, supernatant followed by bio-
tin-conjugated anti-cytokine antibody was added to the
coated wells. After another two hours of incubation,
streptavidin-HRP (horseradish peroxidase) was added to
the wells. After one hour of incubation, streptavidin-HRP
was removed by washing and substrate solution reactive
with HRP was added to the wells. A colored product was
formed in proportion to the amount of cytokine present
in the sample. The reaction was terminated by the addi-
tion of 4 N sulphuric acid and the absorbance was mea-
sured at 450 nm.
Adenosine deaminase (ADA)
ADA activity in the supernatant was determined at 37°C
according to the method of Guisti and Galanti [14] based
on the Berthlot reaction, in which there is the formation
of colored indophenol complex from ammonia liberated
from adenosine and quantified spectrophotometrically
(U.V. Visible spectrophotometer, Systronic-Model). One
unit of ADA is defined as the amount of enzyme required
to release 1 m mol of ammonia/min from adenosine in
standard assay conditions. Results were expressed as
units per litre per minute (U/L/min). The assays were
performed in triplicate and blind to the diagnosis.
Flow cytometric analysis
After performing experiments, the PBMCS obtained
were suspended in PBS and subjected to flow cytometry
analysis to determine CD 4 and CD 8 T cell level/cell
count. Flow cytometry was performed on a fluorescence
activated cell sorter (FACS-SCAN) instrument (Becton
Dickinson Biosciences) Briefly the cells were centrifuged
and 50 ul of sediment was stained using 5 ul antibodies
attached to specific flourochromes against CD8-PER CP,
CD4-PE and CD-3 -FITC (all from Becton Dickinson
Biosciences) and incubated for 30 minutes at room tem-
perature. The cells were again washed and resuspended
in 1 ml saline and subjected to flowcytometry. Cells col-
lected using flow cytometry on a FACS were analyzed
using FlowJo software by gating on the lymphocyte popu-
lation in forward scatter (FSC) and side scatter (SSC).
The gate was set around the lymphocytes to exclude
other cells from analysis. Routinely 10,000 cells per tube
were counted.
Results
Figure 2 shows the IFN-γ levels in supernatants collected
at different time points (0, 24, 48, 72, 96, and 120 hrs) of
short-term cultures of PBMC induced with BCG vaccine.
Booster doses of BCG (2.5 μl) were given after 24 and 48
hrs. An initial increase in IFN-γ secretion in response to
BCG (single dose) was noted until 24 hrs and a decrease
started after 24 hrs. However, after giving a repeat dose of
BCG at 24 and 72 hrs, the IFN-γ levels increased and
were much higher compared to the preboost and without
BCG groups of cultures.
Cellular immune responses are key to an effective pro-
tection against TB. Figure 3 shows the BCG specific anti-
body mediated response (anti-BCG titer) in supernatants
collected at prespecified time intervals from different
experimental groups along with controls. Our data indi-
cate that PBMC induced with booster doses of BCG show
increased specific anti-mycobacterial immune responses
(anti-BCG IgG) compared to preboost group and control
group.
ADA activity in supernatants was determined by the
Guisti and Galanti method. Figure 4 shows the ADA lev-
els in supernatants collected at different point (0, 24, 48,
72, 96, and 120 hrs) of the short-term cultures of PBMC
induced with BCG vaccine. ADA activity was found to
increase immediately after giving the first dose, but
decreased again after 72 hrs. However, the activity
increased at the time when booster dose was given, but
decreased again after 96 hrs.
Figure 5 and Figure 6 shows CD 4 and CD8 levels in
samples collected at pre-specified time intervals from the
preboost, after booster, and without booster groups.
However, no significant change was observed in both
CD4 and CD8 levels after booster dose.
Discussion
Various molecules have been previously investigated, and
currently, many molecules are in process for the develop-
ment of improved vaccine for tuberculosis [14,15].
Despite these efforts, not a single vaccine has been devel-
oped in the last 85 years. The BCG vaccination is still
used in almost every part of the world for protection
against TB, however the outcome is variable. There are
few studies that indicate that BCG gives short term pro-
tection [16]. Like some other well known vaccines which
give better protection after a repeat dose, it was postu-
la t ed by us  t ha t  r epea t  dose  o f  BCG  vac cine  ma y a lso
enhance immunogenicity. Therefore, to study this, we
have evaluated an anti-BCG IgG titer, interferon γ
response, and ADA activity in a peripheral blood mono-
nuclear cells (PBMC) model with repeat dose of BCG
vaccine.
Our data show that induction of repeat dose of BCG in
the PBMC model increased specific antimycobacterial
immune responses (anti-BCG IgG and IFN-γ, T cell
activity-ADA). In other words we have shown that cultur-
ing of human PBMC's with repeat dose of BCG shows
increased memory response to previous immunization.
Recently P M Udani has raised a question of whether
repeat doses are needed in countries where the burden of
TB is high [16]. Our initial work suggests that the efficacy
of BCG may improve with repeat doses. Secondly, these
results may be helpful in designing future experiments inKashyap et al. Journal of Immune Based Therapies and Vaccines 2010, 8:3
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animal models with respect to a booster approach [17].
Ultimately, with the help of all experimental evidences,
India may start repeat immunizations of BCG and may
reduce the burden of TB in future generations.
Three major questions arise while discussing the revac-
cination concept of the BCG vaccine. The first question
is: what is the impact of repeated BCG vaccination on
tuberculin skin test (TST) responses. Uyan et al [13] eval-
uated the TST response after BCG immunization in chil-
dren and observed that the mean induration diameter
increased after repeated BCG vaccination and simultane-
ously increased scar counts. From this study, it is con-
firmed that repeat BCG immunizations alter the TST
response and therefore affect the use of TST in the diag-
Figure 2 IFN-γ levels in supernatants (collected at different time intervals) of short-term cultures of PBMC induced with BCG vaccine. Boost-
er doses of BCG (2.5 μl) were given (indicated with arrow) after 24 & 48 hrs. Cells represent control group without vaccination, Cells+ B represent group 
receiving BCG vaccination without any booster dose, Cells + B1 represent group receiving only one booster dose of vaccine, Cells + B2 represents 
groups receiving two Booster doses of BCG vaccination.
Figure 3 Anti BCG (IgG) levels in supernatants (collected at different time intervals) of short-term cultures of PBMC induced with BCG vac-
cine. Booster doses of BCG (2.5 μl) were given (indicated with arrow) after 24 & 48 hrs. Cells represent control group without vaccination, Cells+ B 
represent group receiving BCG vaccination without any booster dose, Cells + B1 represent group receiving only one booster dose of vaccine, Cells + 
B2 represents groups receiving two Booster doses of BCG vaccinationKashyap et al. Journal of Immune Based Therapies and Vaccines 2010, 8:3
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Figure 4 Level of ADA in supernatants (collected at different time intervals) of short-term cultures of PBMC induced with BCG vaccine. 
Booster doses of BCG (2.5 μl) were given (indicated with arrow) after 24 & 48 hrs. Cells represent control group without vaccination, Cells+ B represent 
group receiving BCG vaccination without any booster dose, Cells + B1 represent group receiving only one booster dose of vaccine, Cells + B2 repre-
sents groups receiving two Booster doses of BCG vaccination
Figure 5 CD4 cells (at different time intervals) in short-term cultures of PBMC induced with BCG vaccine. Booster doses of BCG (2.5 μl) are giv-
en (indicated with arrow) after 24 & 48 hrs. Cells represent control group without vaccination, Cells+ B represent group receiving BCG vaccination 
without any booster dose, Cells + B1 represent group receiving only one booster dose of vaccine, Cells + B2 represents groups receiving two Booster 
doses of BCG vaccinationKashyap et al. Journal of Immune Based Therapies and Vaccines 2010, 8:3
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nosis of TB infection in this group of children. Another
important question is whether a repeat dose of BCG
causes tuberculosis or not. We have searched the litera-
ture to answer this question and we have not found any
evidence which suggests that repeat BCG immunization
ca uses TB. In fact, M enzies et al ha ve report ed t ha t a
repeat BCG immunization is rarely the cause of TB infec-
tion [18]. Thirdly whether repeat BCG dose will give
enhanced protection in humans even though, observed in
invitro PBMC studies can only be decided after proper
controlled animal model and clinical studies.
It is important to critically evaluate the results pre-
sented in this study which has some major limitations
that needs to be evaluated while considering BCG revac-
cination. The data shows an increase in IgG in BCG stim-
ulated PBMC, which is an encouraging finding. However,
it will be very important to measure IgG response to non-
related immunogen (control Ag) to rule out any non-spe-
cific immune response. Secondly, the risk of development
of TB cannot be studied with the developed in vitro
model and therefore the study requires the development
of an animal model. The other limitation in the present
model is inability to observe the immune response in
PBMC after a particular time (120 hrs in our study).
However, this preliminary study with a PBMC model pro-
vides valuable information for the design of appropriate
animal models for further studies.
Conclusion
The repeat BCG stimulation of PBMC obtained from
BCG vaccinated individuals shows enhanced immune
activation with respect to increased anti-BCG titre, IFN-γ
and ADA activity without concomitant increase in CD4
and CD8 cells. This study provides some basics data in
future experiments in animal models with respect to
repeat BCG vaccination.
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